CCRDF President Tom Sjostrom announced the agency’s approval of the company’s second and third drug therapies for the chronic wasting disease, Chronic Traumatic Encephalopathy (CTE).The approval is a result of a review of the drugs’ clinical trial data, a decision made by the agency last year after CCRDP submitted additional evidence of effectiveness.CCRDEP is in the process of evaluating CTE […]